ArticleBreast (Edinburgh, Scotland)2026
Impact of depression on treatment response and survival among patients with breast cancer: A multi-institutional retrospective cohort study.
Article in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to investigate the relationship between depression and the risks of breast cancer recurrence and mortality.
methodsThis retrospective cohort study included 2667 breast cancer patients hospitalized across four hospitals in China between January 1, 2016, and December 31, 2019, with follow-up until December 31, 2025. We identified patients diagnosed with depressive disorder and collected demographic characteristics, tumor pathological features, and clinical treatment data. Primary outcomes were recurrence and mortality. Multi-variable Cox proportional hazards models were used, adjusting for age, tumor stage, estrogen receptor (ER)/progesterone receptor (PR)/human epidermal growth factor receptor-2 (HER2) status, chemoradiotherapy, surgical method, marital status, and body mass index (BMI).
resultsAmong 2667 breast cancer patients, 343 (12.8%) were diagnosed with depression disorder. Multivariable analysis showed depressed patients had 60% higher recurrence risk (HR = 1.60, 95% CI:1.21-2.13) and 70% higher breast cancer-specific mortality risk (HR = 1.70, 95% CI:1.20-2.41). In all ER/PR subgroups, depression consistently increased risks (HR > 1), particularly in HER2-positive patients. A significant interaction existed between radiotherapy and depression on mortality (p =0.017), with elevated risk more evident in patients who received radiotherapy. Across all surgical types, depressed patients consistently showed higher risks.
conclusionsBreast cancer patients with comorbid depression tend to have inferior clinical outcomes. Future research should explore the underlying mechanisms linking depression to cancer progression and evaluate targeted interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.